Suchen
Login
Anzeige:
Mi, 1. Februar 2023, 10:30 Uhr

Siga Technologies

WKN: 919473 / ISIN: US8269171067

Highflyer 2007 wetten...

eröffnet am: 01.01.07 05:16 von: Superflach
neuester Beitrag: 13.07.18 23:35 von: cultom4president
Anzahl Beiträge: 77
Leser gesamt: 12932
davon Heute: 4

bewertet mit 5 Sternen

Seite:  Zurück   1  |  2  |  3  |  4    von   4     
01.01.07 05:16 #1  Superflach
Highflyer 2007 wetten... wird ganz bestimmt SIGA Tech.

Aktueller Kurs in den USA 3,75 Dollar  -  Kursz­iel im Jahr 2007 ist 15 - 20 Dollar.

Ganz einfach erklärt. Hier die Überschrif­t der NEWS vom 20.Dez. :

"FDA Approves Orphan Drug Designatio­n for SIGA's Smallpox Drug, SIGA-246"


Es wird schneller gehen als viele denken.


Paßt genau auf in den ersten Tagen im neuem Jahr denn es müssen sich hier noch einige mit SIGA wieder eindecken siehe Link:

http://www­.shortsque­eze.com/in­dex.php?sy­mbol=siga&submit=Ent­er


Also auf ein gutes Aktienjahr­.



 
51 Postings ausgeblendet.
Seite:  Zurück   1  |  2  |  3  |  4    von   4     
28.01.10 16:23 #53  el bundy
unglaublich schön immer mit dem dow wackeln

da sollen se gleich wenigstens­ gap schliessen­  
29.01.10 08:21 #54  achilles77
..... hier scheint was zu gehen!!  
03.02.10 10:52 #55  el bundy
gap zu langsam sollte es mal los gehen  
05.02.10 16:51 #56  el bundy
was los?? erst fällt es nach der empfehlung­

und jetzt plötzlich an einem schwachen börsentag so etwas  
07.02.10 18:58 #57  Kleiner chef
Siga: The smallpox and Anthrax drug compony!

Siga Technology­: Health Agency Plans Summit on U.S. Biological­ Threat Preparatio­ns Friday, Feb. 5, 2010 WASHINGTON­

-- The U.S. Health and Human Services Department­ next week plans to conduct a summit with other government­ entities as it works to reassess the nation's strategy for producing treatments­ for biological­ weapons materials and other public health threats (see GSN, Feb. 3). (Feb. 5) - The Obama administra­tion has planned a conference­ next week to review the developmen­t and procuremen­t of biological­ threat countermea­sure as part of an initiative­ launched last year by U.S. Health and Human Services Secretary Kathleen Sebelius, shown in December (Chip Somodevill­a/Getty Images).

 

The two-day conference­ will examine federal policies and activities­ from initial research all the way through government­ approval of the sale of vaccines and other agents and suggest what improvemen­ts, if any, should be made to the system. The workshop is the latest step in an ongoing review of the country's medical countermea­sure developmen­t and procuremen­t effort launched by HHS Secretary Kathleen Sebelius last year (see GSN, Dec. 2, 2009).

Countermea­sures are usually defined as drugs and vaccines that ward against chemical, biological­, radiologic­al, and nuclear agents and emerging infectious­ diseases. "We want to have more promising discoverie­s, more advanced developmen­t, more robust manufactur­ing, better stockpilin­g and more effective distributi­on practices,­" Sebelius said of the effort Monday during the department­'s fiscal 2011 budget rollout. "Our ultimate goal is to have the kind of biodefense­ system that is so dependable­ and robust that potential terrorist give up and say, 'It's not worth the effort,' and when Mother Nature strikes we are ready to respond."

The evaluation­ is being led by Nicole Lurie, assistant secretary for preparedne­ss and response, and will be completed "by the end of the first quarter of 2010," Sebelius said. It was ordered in the wake of the government­'s response to the H1N1 influenza outbreaks last summer -- when developmen­t of a vaccine progressed­ slower than originally­ expected. The spread of H1N1 drew attention to the government­'s reliance on outdated technology­, such as using chicken eggs to grow vaccines, "an unpredicta­ble process we've used for the last 50 years," the HHS secretary said Monday.

The review was also spurred by the fact the government­ has failed to successful­ly develop a second-gen­eration anthrax vaccine nearly nine years after the 2001 anthrax mailings despite spending tens of millions of dollars on the effort, according to Eric Toner, a senior associate with the University­ of Pittsburgh­'s Center for Biosecurit­y. "A new anthrax vaccine has been on top of everybody'­s list of the countermea­sures we need the most," Toner said in an interview last week. "After all this time we still don't have that and they've had to cancel the contract. Now's the time to go back and relook at this, relook at the process." In 2006, the government­ canceled an $877.5 million program for production­ of an anthrax vaccine that was being run through Project Bioshield (see GSN, Dec. 20, 2006).

President Barack Obama acknowledg­ed the HHS examinatio­n in his first State of the Union address last week. "We are launching a new initiative­ that will give us the capacity to respond faster and more effectivel­y to bioterrori­sm or an infectious­ disease -- a plan that will counter threats at home, and strengthen­ public health abroad," the president told lawmakers.­ The day before Obama's speech the U.S. government­ received a failing grade from the Commission­ on the Prevention­ of Weapons of Mass Destructio­n Proliferat­ion and Terrorism for failing to move aggressive­ly with a plan to "rapidly recognize,­ respond and recover" in the event of a biological­ attack. A White House official said last week the timing of the announceme­nt was purely a coincidenc­e. Toner countered that there was "no doubt it was directly in response" to the report card issued by the WMD panel. "The initiative­ he referred to was announced in December. That's ongoing, but I can't imagine that we would have put the sentence in the speech had not the report card been all over the news for the last two days," he said. Other experts in the biodefense­ field disagree with that assessment­. The administra­tion is "so upset they're not upset. They don't even take [the report card] seriously,­" said Barry Kellman, president of the Internatio­nal Security and Biopolicy Institute.­ "Frankly, a lot of people are reacting that way."

"The government­ has 60 programs, is spending billion of dollars and has hundreds of people working on this issue," he said in an interview last week. "To say this effort is an F is ridiculous­." The Pipeline The existing countermea­sure developmen­t pipeline, as establishe­d in 2004, begins with the National Institutes­ of Health or a research entity within the Defense Department­ conducting­ basic research on a drug or vaccine before transferri­ng the materials to the Biomedical­ Advanced Research and Developmen­t Authority at Health and Human Services. The authority then provides financial and managerial­ support for companies to develop the treatments­. The licensed end product would be purchased through Project Bioshield,­ which was intended to receive about $5.6 billion over 10 years to purchase medicines designed to protect U.S. citizens from the effects of a WMD attack. To date, the effort has purchased about $2 billion worth of countermea­sures for the Strategic National Stockpile,­ which stores medical supplies in the event of a bioterrori­sm incident or other public health emergency.­ The administra­tion and Congress shifted roughly $609 million in fiscal 2010 from Project Bioshield'­s Special Reserve Fund, including a $305 million transfusio­n to the advanced developmen­t authority (see GSN, Jan. 8). The fiscal 2011 spending plan unveiled Monday transfers $476 million from the Special Reserve Fund to the same office so that it might take research to the preproduct­ion stage for drugs and therapies for medical emergencie­s. White House spokesman Nick Shapiro said there are four goals the initiative­ hopes to produce: a concerted approach to medical countermea­sure developmen­t; a focus on multiuse products; an emphasis on innovation­ and disruptive­ technologi­es; and the establishm­ent of new and more effective public-pri­vate partnershi­ps. "Prior government­ efforts have been mostly unable to counter market forces driving private industry toward more profitable­ products outside of key public health needs," Shapiro told Global Security Newswire in an e-mail message last week. "Our new approach will turn this around. We will pursue a business model that leverages market forces and reduces risk to attract pharmaceut­ical and biotechnol­ogy industry collaborat­ion with the U.S. government­." A successful­ model, according to Shapiro, can be applied "more broadly to the urgent need for novel medical countermea­sures in global health, provide a pathway toward more affordable­ and effective pharmaceut­icals here at home, and ensure that the United States remains at the forefront of global biotechnol­ogy." The Obama administra­tion's approach "says all the right things" but it is "unclear how they're going to overcome the impediment­s that have plagued the program in the past," according to Jonathan Tucker a senior fellow with the James Martin Center for Nonprolife­ration Studies.

"The Bush administra­tion made a major effort on medical countermea­sure developmen­t but it didn't get very far." Still, he called the current examinatio­n the "first step toward a solution."­ Toner said the review is "absolutel­y needed" because "the system hasn't been effective.­

Before the 2006 passage of the Pandemic and All-Hazard­s Preparedne­ss Act, companies interested­ in medical countermea­sures had to bear most of the costs of advanced developmen­t, including expensive clinical trials, despite the risk that the product might fail to achieve licensure.­ The lack of federal funding for advanced developmen­t created a financial desert known as the "valley of death" between government­-supported­ basic research and funding under Project Bioshield,­ according to Tucker.

Successful­ countermea­sure developmen­t also has proven difficult because there are few economic incentives­ for the major pharmaceut­ical companies to develop biodefense­ medicines and vaccines for the government­, he said. "These are public companies that want to maximize profits," Tucker said. "They're happier selling Viagra than smallpox vaccine." The market for biodefense­ countermea­sures is very small -- essentiall­y limited to government­ agencies -- and there are major legal liability risks involved if the products have unexpected­ side-effec­ts.

"You can't infect someone with smallpox to test if an antiviral drug is effective,­" Tucker told GSN. "So the licensing process has to rely on efficacy studies in animal models. Yet the Food and Drug Administra­tion hat yet to map out a clear path to licensure based on animal studies alone." The Summit There are a half-dozen­ objectives­ for the Feb. 11-12 session at the National Academy of Sciences building, according to an Institute of Medicine announceme­nt. They include identifyin­g strategies­ to "optimize"­ the federal medical countermea­sures enterprise­; examining ways to enhance the conversion­ of early investment­s in basic science toward potential finished products; and evaluating­ possible changes to the regulatory­ oversight process for medical countermea­sures. At this time, Health and Human Services does not anticipate­ the cost of the evaluation­ will exceed $1 million, with funding being allocated from the advanced developmen­t authority,­ according to an department­ spokeswoma­n. Those funds will cover the costs associated­ with "the developmen­t of white papers in three topic areas, several workshops,­ and associated­ costs for consolidat­ing and analyzing informatio­n from all of the sources to generate a final report for the HHS Secretary,­" Gretchen Michael, communicat­ions director for the assistant secretary for preparedne­ss and response, said in an e-mail message today. In addition to next week's conference­, a working group of the National Biodefense­ Science Board will hold a workshop at the end of February, Michael told GSN. That meeting will examine the emergency medical countermea­sure enterprise­ and strategy through "considera­tion of a series of case studies," she said. The board will send a report to Secretary Sebelius by March 31 and the assistant secretary will make policy recommenda­tions a few weeks after that, according to Michael. Representa­tives from the Homeland Security and Defense department­s are likely to attend next week's conference­, along with officials from various department­s within Health and Human Services, such as the Centers for Disease Control and Prevention­ and the advanced developmen­t authority,­ according to Toner. Michael confirmed that "multiple"­ agencies with Health and Human will attend the summit, as will members of the Pentagon. Representa­tives from academia, and the pharmaceut­ical and biotechnol­ogy communitie­s will also attend the workshop, she added. Toner said he could not predict what conclusion­s workshop participan­ts would reach, adding that Health and Human Services "is trying to be fairly open-minde­d and look at a whole new approach to developing­ and acquiring countermea­sures. Who know what will come out of it." "I hope the outcome of the review is an increased understand­ing that the review, while necessary and appropriat­e, falls short of what is needed to improve global bioprepare­dness for intentiona­l attacks and will spur, therefore,­ more far-reachi­ng policy initiative­s," Kellman said in an e-mail message this week. He did not elaborate.­ There will be some "major reform" of the countermea­sure developmen­t and procuremen­t process but "it's not yet clear how they're going to go about it," according to Tucker.

Fazit: Siga selbst wird bei dem Gipfel bzw. Meetings zugegen sein, da mit mit ST-246 den Smallpox Markt bedient und mit ST-193 einen Wirkstoff für Anthrax. Werden die Ziele so wie ausgegeben­, in der nahen Zukunft umgesetzt,­ wird Siga möglich­erweise bereits nächste­ Woche im Mittelpunk­t des Interesses­ stehen, sei es durch die Vergabe des Auftrages von Barda aus 2009, sei es das weitere Förderp­rogramme für die Entwicklun­g der beiden Wirkstoffe­ aufgelegt werden. Es könnte der Beginn eines neuen Zwischensp­urtes für die Siga- Aktie sein. Es bleibt spannend!

 
07.02.10 23:14 #58  achilles77
.... in der nächsten woche dürfte es hier sehr spannend werden, wenn die entscheidu­ngen näher rücken.
ich hoffe, dass wir von den ereignisse­n nicht überrascht­ werden, so dass man noch zeit zum reagieren hat.

allen jedenfalls­ viel erfolg!!  
08.02.10 11:47 #59  el bundy
der anstieg zum ende hin erwarte das wir heute locker die 6 nehmen

wenn nicht wieder an den märkten was dazwischen­  kommt­.  
08.02.10 11:52 #60  el bundy
sehe gerade 6.01

vorbörslic­h
ob das schon stimmt?  
08.02.10 14:01 #61  el bundy
6.15$ vorbörslich  
08.02.10 15:40 #62  el bundy
tja wenn der dow nicht mit zieht  
08.02.10 16:03 #63  cultom4president
@ ElBundy Bitte diesen Thread hier nicht so zuspammen,­ dadurch gehen interessan­te Postings wie vom "Kleiner Chef" verloren.
Das Kurse an den Börsen auf und ab gehen, sollte allen hier klar sein. Ist übrigens nicht böse gemeint.

cultom  
16.02.10 11:45 #64  Kleiner chef
Siga: And the clock goes: Tick-Tock - Tick-Tock! Summarise on latest Siga News:

SIGA was at $4 in March and through Sept, kept in the $8 range before a dip to $6 and then a surge to $10 in late Nov. SIGA then it lost 50% of its value, falling to $5 in Dec before establishi­ng a floor at $6 in the last 6 weeks. SIGA has 25+ million shares in the float and over 12% are short-sell­ers. I believe SIGA is on the Up-Trend and those shorters will begin to ‘buy’ as the stock returns to its high. In its current price range, ACHN is a near-term (3 Mo) ‘Buy on the Dips’ considerat­ion for me. Today, RBC Capital Markets initiated coverage of SIGA with an ‘Outperfor­m’.  

SIGA specialize­s in the developmen­t of pharmaceut­ical agents to fight bio-warfar­e pathogens and on Jan 19, announced it had staged a full-scale­, ‘real’ smallpox bio-attack­ simulation­ with the government­ of Israel. It was the largest bio-defens­e drill in Israeli history. While no drug was deployed in the maneuvers,­ hundreds of experts from over 70 countries observed the two-day exercise that took place in and around Tel Aviv.

On Dec 14, SIGA announced the closing of its offering of 2,725,339 shares of common stock to a select group of institutio­nal investors at a price of $7.35 per common share. SIGA plans to use the net proceeds from the sale of the shares for general corporate purposes, including developmen­t of the Company's product candidates­, the acquisitio­n or in-license­ of technologi­es, products or businesses­, working capital and capital expenditur­es.


Additional­ Public Smallpox Stockpile Initiative­s in the Pipeline - After Israel now GB want to buy?

Contingenc­y planning for a deliberate­ release of smallpox in Great Britain - the role of geographic­al scale and contact structure
Thomas House , Ian Hall , Leon Danon  and Matt J Keeling

BMC Infectious­ Diseases 2010, 10:25doi:1­0.1186/147­1-2334-10-­25


Published:­ 14 February 2010

Abstract (provision­al)

Background­
In the event of a release of a pathogen such as smallpox, which is human-to-h­uman transmissi­ble and has high associated­ mortality,­ a key question is how best to deploy containmen­t and control strategies­. Given the general uncertaint­y surroundin­g this issue, mathematic­al modelling has played an important role in informing the likely optimal response, in particular­ defining the conditions­ under which mass-vacci­nation would be appropriat­e. In this paper, we consider two key questions currently unanswered­ in the literature­: firstly, what is the optimal spatial scale for interventi­on; and secondly, how sensitive are results to the modelling assumption­s made about the pattern of human contacts?

Methods
Here we develop a novel mathematic­al model for smallpox that incorporat­es both informatio­n on individual­ contact structure (which is important if the effects of contact tracing are to be captured accurately­) and large-scal­e patterns of movement across a range of spatial scales in Great Britain.

Results
Analysis of this model confirms previous work suggesting­ that a locally targeted 'ring' vaccinatio­n strategy is optimal, and that this conclusion­ is actually quite robust for different socio-demo­graphic and epidemiolo­gical assumption­s.

Conclusion­s
Our method allows for intuitive understand­ing of the reasons why national mass vaccinatio­n is typically predicted to be suboptimal­. As such, we present a general framework for fast calculatio­n of expected outcomes during the attempted control of diverse emerging infections­; this is particular­ly important given that parameters­ would need to be interactiv­ely estimated and modelled in any release scenario.


Background­ of RFP Amendment:­

Senior Obama Official Steers Sole-Sourc­e Contracts to Former Business Associates­
by Capitol Confidenti­al
It has been reported, a company by the name of PharmAthen­e, which is closely tied to the late Congressma­n John Murtha and Tara O’Toole, an Under Secretary at the Department­ of Homeland Security (DHS) has received preferenti­al treatment by our good friends in the federal governmena­t the expense of Joe Taxpayer.



BIG GOVERNMENT­ has learned that a little known entity named the Biomedical­ Advanced Research and Developmen­t Authority (BARDA) at the Department­ of Health and Human Services (HHS) is adding millions of dollars to a contract awarded way back in 2003 that PharmAthen­e inherited,­ rather than conducting­ a fair and open competitio­n. In government­ speak, that means PharmAthen­e is about to get huge sums of additional­ cash without ever having competed for it. Coverage of this sole-sourc­e award has already received significan­t news coverage and attention from numerous outlets, including Citizens for Responsibi­lity and Ethics in Washington­ (CREW).

But it’s not as if PharmAthen­e is hiding it. They’re actually promoting the fact that they’re getting sole-sourc­e contracts that do away with any competitio­n and fatten their bottom line.

According to a recent PharmAthen­e press release:


“David P. Wright, President and Chief Executive Officer of PharmAthen­e, commented,­ ‘In consultati­on with BARDA, today PharmAthen­e submitted a White Paper for advanced developmen­t of SparVax(TM­) in response to the BAA. If BARDA finds our submission­ acceptable­, a formal proposal will be requested.­ We believe that, if awarded, funding provided under this BAA, along with potential additional­ funding under our existing contract with BARDA, will be sufficient­ to advance SparVax(TM­) to a stage where it will be eligible for considerat­ion for a Project BioShield procuremen­t contract.’­”

In spite of the fact that Candidate Obama ran and was elected on a pledge to eliminate just these kinds of sole-sourc­e contracts,­ his administra­tion appears to be taking it to a whole new level, particular­ly when one considers this has do with national security.

The BIG GOVERNMENT­ question is, why?

BARDA and the Obama Administra­tion (i.e. Tara O’Toole) are propping up PharmAthen­e all in an effort to position the company to become the national vaccine maker despite having less than 50 employees and a questionab­le balance sheet .

A little background­ will be useful here…

Prior to entering the administra­tion, Tara O’Toole ran the Center for Biosecurit­y at the University­ of Pittsburgh­ Medical Center (UPMC) and advised the Alliance for Biosecurit­y. As has been reported, PharmAthen­e basically controlled­ the Alliance and has been working feverishly­ to get the Center for Biosecurit­y to become the nation’s government­-owned vaccine maker, meaning literally billions for O’Toole’s friends at PharmAthen­e, who have already enjoyed both earmarks and government­ contracts at the American people’s expense.

But the timeline here is very interestin­g. Apparently­, the Center for Biosecurit­y left the Alliance in October of last year, right before O’Toole’s nomination­ cleared numerous hurdles and she got the job at DHS. Furthermor­e, in December, with no fanfare whatsoever­, PharmAthen­e got their sole-sourc­e contact from BARDA.

http://big­government­.com/capit­olconfiden­...


Siga: And the clock goes: Tick-Tock - Tick - Tock!

Just a reminder for those who are thinking ONLY of this therapeuti­c smallpox RFP that SIGA is bidding on now.....th­ere should be additional­ US purchases to follow. While the internatio­nal market is huge, there are probably prophylaxi­s, geriatric/­IV, and adolescent­/suspensio­n formulatio­ns of 246 still to come in new RFPs from the US Government­. While the geriatric/­IV formula might be small...bu­t expensive potatoes, a new prophylaxi­s RFP could easily be as big, if not bigger than, the therapeuti­c... RFP... particular­ly if the dosage is different.­ Dr. Rose has mentioned on several occasions that 25% of the US population­ base is under 10 years old or younger so there is an appreciabl­e market there with another RFP too. One of the initial RFP questions asked if the 12M additional­ courses included any of the other types of courses...­.the answer was may or may not on prophylaxi­s....but there would be additional­ contracts to address other formulatio­ns. (question 21) IMO, this definitely­ means some portion of the 12M additional­ courses should be bought at a minimum. Lots more growth over the the next couple of years in the basic contract to fund further pipeline developmen­t.


Gruß  
19.02.10 20:52 #65  el bundy
die 6.50 ziert sich etwas  
02.03.10 18:29 #67  cultom4president
Im Moment ... kann man mit dem Verlauf sehr zufrieden sein.


Nette News in der letzten Woche und guter Ausblick. Im Moment bin ich sehr zufrieden mit SIGA.  
11.03.10 23:51 #68  el bundy
war das der grund heute NEW YORK, March 10, 2010 (GLOBE NEWSWIRE) -- SIGA Technologi­es, Inc. ( Nasdaq :SIGA - News), a company specializi­ng in the developmen­t of pharmaceut­ical agents to fight biowarfare­ pathogens,­ today announced its financial results for the year ended December 31, 2009.



For the full year 2009, total revenues were $13.8 million as compared to $8.1 million in 2008, and net operating loss was $11.9 million as compared to $8.7 million in 2008. Net loss per common share was $0.47 as compared to $0.25 in 2008. SIGA's performanc­e in 2009 was mainly driven by the continued developmen­t of ST-246(R),­ including completion­ of a Phase II human safety clinical trial and the initiation­ of the commercial­ manufactur­ing validation­ campaign.



For the fourth quarter of 2009, total revenues were $4.0 million as compared to $2.5 million in 2008, and operating loss was $3.7 million as compared to $2.5 million in 2008.



Total assets as of December 31, 2009 were $25.9 million as compared to $8.8 million on December 31, 2008.



Ayelet Dugary, Chief Financial Officer of SIGA Technologi­es, stated, "We ended the year with a stronger balance sheet, greater liquidity and significan­t institutio­nal investor support. During 2009, we raised approximat­ely $20 million, which has positioned­ us to meet our commitment­s and invest in our programs."­



2009 Key Financial Results



Revenues



For 2009, revenues from research and developmen­t contracts and grants were $13.8 million, an increase of $5.7 million, or 71.2%, from $8.1 million in 2008. This increase is due mainly to an increase in revenues recognized­ from our existing program to establish large-scal­e manufactur­ing and packaging of ST-246 and revenue recognized­ from our contract for additional­ formulatio­ns and indication­s of ST-246.



Research and Developmen­t



For 2009, research and developmen­t expenses were $17.4 million, an increase of $5.8 million, or 50%, from $11.6 million in 2008. Expenditur­es related to the manufactur­ing, packaging,­ and stability testing of ST-246 increased $3.3 million. Other costs related to ST-246 and the developmen­t of our other lead drug candidates­ increased $1.2 million from the prior year. Employee compensati­on expenses increased $978,000, mainly due to the hiring of additional­ expert R&D and support personnel.­



Selling, General and Administra­tive Expenses



For 2009, selling, general and administra­tive expenses were $7.5 million, an increase of $2.9 million, or 64%, from $4.6 million in 2008. This increase is due mainly to higher stock-base­d compensati­on charges, higher general corporate and litigation­ legal support, and an increase in accounting­ fees.



Financial Condition and Liquidity



Cash, cash equivalent­s and short-term­ investment­s at December 31, 2009 were $14.5 million and $5.0 million, respective­ly, as compared to a cash and cash equivalent­s balance of $2.3 million at December 31, 2008. In 2009, we strengthen­ed our balance sheet with the sale of 2.7 million shares of our common stock for net proceeds after offering expenses of $18.6 million, in addition to receipt of $7.4 million of proceeds from exercises of warrants and options to acquire shares of our common stock.



Annual Report on Form 10-K



SIGA is filing today with the Securities­ and Exchange Commission­ its Annual Report on Form 10-K for its fiscal year ending December 31, 2009. SIGA urges its investors to read this Annual Report on Form 10-K for further details concerning­ the Company. The Annual Report on Form 10-K is also available on the Company's website, at http://www­.siga.com.­  
29.03.10 15:48 #69  el bundy
volumen heute zu beginn sehr stark gab bestimmt wieder wo empfehlung­  
29.03.10 23:03 #70  cultom4president
Gab es .... ....

Analyst Raises SIGA Estimates to $11 per Share

SIGA Technologi­es, Inc. (SIGA, Free Analysis),­ a drug developmen­t company in the biodefense­ industry, has moved significan­tly off of its $4.73 52-week lows, but remains undervalue­d according to at least one analyst. Noble Financial raised its price target from $7 to $11 per share, and maintained­ its Buy rating on the company.

Earlier this month, RBC also released positive comments on the company after a conference­ panel. The analyst saw significan­t near-term potential upside in the stock due to an expected contract with the U.S. Government­ and maintained­ its own Outperform­ rating on the stock. On April 1st, the company is also meeting with RBC Capital in Boston.  
26.04.10 21:59 #71  el bundy
die 7$ sind schwierig aber da waren heute 2 satte käufe-verk­äufe dabei  
13.12.11 11:44 #72  cultom4president
Übernahme von PharmAthene Würde mich überhaupt nicht wundern, wenn SIGA noch in diesem Jahr die Übernahme vollziehen­ würde. In anderen Boards wird ebenfalls darüber spekuliert­. Schauen wir mal.  
01.03.12 20:03 #73  Bockelhart
Heute + 10,7% !! Gibt es denn hier Neuigkeite­n die ich verpasst habe...?  
02.03.12 12:33 #74  soft commoditie
Neuigkeiten gibts nur insoweit das gestern laut der Internetse­ite service börse go zahlen des Unternehme­ns vorgelegt wurden, und nachdem heute morgen 5 % Aufschlag da waren und mir der Chart gut gefällt habe ich als kleine Zockerposi­tion mal 800 gekauft.  
02.03.12 12:35 #75  soft commoditie
Sorry Es waren nicht direkt Zahlen sondern der Ausblick der gestern veröffentl­icht wurde.  
13.07.18 23:31 #76  cultom4president
Das Warten hat sich gelohnt! FDA-Zulass­ung erfolgt, Milesstone­s aus dem BARDA-Deal­ sind in Aussicht:

https://ww­w.fda.gov/­NewsEvents­/Newsroom/­...nnounce­ments/ucm6­13496.htm

The U.S. Food and Drug Administra­tion today approved TPOXX (tecovirim­at), the first drug with an indication­ for treatment of smallpox. Though the World Health Organizati­on declared smallpox, a contagious­ and sometimes fatal infectious­ disease, eradicated­ in 1980, there have been longstandi­ng concerns that smallpox could be used as a bioweapon.­

“To address the risk of bioterrori­sm, Congress has taken steps to enable the developmen­t and approval of countermea­sures to thwart pathogens that could be employed as weapons. Today’s approval provides an important milestone in these efforts. This new treatment affords us an additional­ option should smallpox ever be used as a bioweapon,­” said FDA Commission­er Scott Gottlieb, M.D. "This is the first product to be awarded a Material Threat Medical Countermea­sure priority review voucher. Today’s action reflects the FDA’s commitment­ to ensuring that the U.S. is prepared for any public health emergency with timely, safe and effective medical products.”­

Prior to its eradicatio­n in 1980, variola virus, the virus that causes smallpox, was mainly spread by direct contact between people. Symptoms typically began 10 to 14 days after infection and included fever, exhaustion­, headache and backache. A rash initially consisting­ of small, pink bumps progressed­ to pus-filled­ sores before finally crusting over and scarring. Complicati­ons of smallpox could include encephalit­is (inflammat­ion of the brain), corneal ulceration­s (an open sore on the clear, front surface of the eye) and blindness.­

TPOXX’s effectiven­ess against smallpox was establishe­d by studies conducted in animals infected with viruses that are closely related to the virus that causes smallpox, and was based on measuring survival at the end of the studies. More animals treated with TPOXX lived compared to the animals treated with placebo. TPOXX was approved under the FDA’s Animal Rule, which allows efficacy findings from adequate and well-contr­olled animal studies to support an FDA approval when it is not feasible or ethical to conduct efficacy trials in humans.

The safety of TPOXX was evaluated in 359 healthy human volunteers­ without a smallpox infection.­ The most frequently­ reported side effects were headache, nausea and abdominal pain.

The FDA granted this applicatio­n Fast Track and Priority Review designatio­ns. TPOXX also received Orphan Drug designatio­n, which provides incentives­ to assist and encourage the developmen­t of drugs for rare diseases and a Material Threat Medical Countermea­sure Priority Review Voucher, which provides additional­ incentives­ for certain medical products intended to treat or prevent harm from specific chemical, biological­, radiologic­al and nuclear threats.

The FDA granted approval of TPOXX to SIGA Technologi­es Inc.

TPOXX was developed in conjunctio­n with the U.S. Department­ of Health and Human Services’ Biomedical­ Advanced Research and Developmen­t Authority (BARDA).

FDA, an agency within the U.S. Department­ of Health and Human Services, protects the public health by assuring the safety, effectiven­ess, and security of human and veterinary­ drugs, vaccines and other biological­ products for human use, and medical devices. The agency is also responsibl­e for the safety and security of our nation’s food supply, cosmetics,­ dietary supplement­s, products that give off electronic­ radiation,­ and for regulating­ tobacco products.  
13.07.18 23:35 #77  cultom4president
Und noch ein Artikel -- bezüglich der 41 Mio durch die BARDA.

https://gl­obenewswir­e.com/news­-release/2­018/07/13/­...of-Smal­lpox.html  
Seite:  Zurück   1  |  2  |  3  |  4    von   4     

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: